HeartGenetics will attend the world‘s largest medical marketplace November 16th to 19th 2015 in Düsseldorf, Germany.
Get in contact
Please send us an email to email@example.com to arrange a meeting during the trade fair.
HeartGenetics Products and Services
The HeartGenetics technology, based on a DNA MICROCHIP array platform for genetic analysis with clinical utility, has solid trade secrets and a provisional patent application (PPA). The team has developed a set of genetic tests that can be prescribed in several areas, e.g.: Obstetrics, Cardiac, Inflammation and Pharmacogenomics.
Current offer comprises six tests addressing the following pathologies:
- Hereditary Thrombophilia (TromboGene™),
- Arterial Hypertension (DNArterial®),
- Familial Hypercholesterolemia (LipoGene™)
- Hypertrophic cardiomyopathy (SportGene™ and HCMScreening™ )
The HeartGenetics’ DNArterial® genetic test (PPA pending) is pioneer in the simultaneous analysis of 57 SNPs (37 genes) associated with the regulation and/or dysfunction of five metabolic axes and in considering genetic biomarkers linked with the pharmacological response to anti-hypertensive therapies.
In addition, it has also launched three tests targeting cardiovascular Pharmacogenetics:
- Warfarin Pharmacogenetics
- Simvastatin Pharmacogenetics
- Clopidogrel Pharmacogenetics
Our core competences also comprise the development of new high-tech bioinformatics tools and databases that support highly accurate analysis and integration of both genetic, phamacogenetics and clinical data.
The innovative clinical decision support and reporting systems, HEARTDECODE®, allow clinicians and practitioners to perform a more accurate diagnosis, prognosis and risk stratification, thanks to a more comprehensive, more simple to read and more straight to the point reports. These software systems are not dependent of the genomic technologies used to obtain the genetic data and therefore should be seen as independent products with its own market.
Download the complete Genetic Testing Panel
More information here
Read more archived news here
This article was published on November 4, 2015.